Comparison of acute kidney injury during treatment with vancomycin in combination with piperacillin-tazobactam or cefepime

Diane M. Gomes, Carmen Smotherman, Amy Birch, Lori Dupree, Bethany J. Della Vecchia, Dale Kraemer, Christopher A. Jankowski

Research output: Contribution to journalArticle

89 Citations (Scopus)

Abstract

Study Objective To evaluate the observed incidence of acute kidney injury (AKI) in adult patients receiving either piperacillin-tazobactam and vancomycin or cefepime-vancomycin for more than 48 hours. Design Retrospective matched cohort. Setting Large academic medical center. Patients Adult patients without preexisting renal dysfunction admitted over an 8-month time period who received either the combination of piperacillin-tazobactam and vancomycin or cefepime-vancomycin for more than 48 hours were evaluated for AKI, defined by the Acute Kidney Injury Network criteria. Measurements and Main Results A total of 224 patients receiving either antimicrobial combination were evaluated for AKI. The incidence of AKI was significantly higher in the piperacillin- tazobactam and vancomycin group (34.8%) compared with the cefepime-vancomycin group (12.5%) in the unmatched analysis (p<0.0001). After adjusting for potential sources of bias through propensity score matched pairs and conditional logistic regression, piperacillin-tazobactam and vancomycin combination therapy (p=0.003) was an independent predictor of AKI. There were no significant differences in time to AKI or hospital length of stay between groups. Conclusions The results of this study suggest that there may be an association between piperacillin-tazobactam and vancomycin combination therapy and increased incidence of AKI.

Original languageEnglish (US)
Pages (from-to)662-669
Number of pages8
JournalPharmacotherapy
Volume34
Issue number7
DOIs
StatePublished - Jan 1 2014
Externally publishedYes

Fingerprint

Vancomycin
Acute Kidney Injury
Therapeutics
Length of Stay
Incidence
Propensity Score
tazobactam drug combination piperacillin
cefepime
Logistic Models
Kidney

Keywords

  • acute kidney injury
  • cefepime
  • nephrotoxicity
  • piperacillin-tazobactam
  • vancomycin

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Medicine(all)

Cite this

Gomes, D. M., Smotherman, C., Birch, A., Dupree, L., Della Vecchia, B. J., Kraemer, D., & Jankowski, C. A. (2014). Comparison of acute kidney injury during treatment with vancomycin in combination with piperacillin-tazobactam or cefepime. Pharmacotherapy, 34(7), 662-669. https://doi.org/10.1002/phar.1428

Comparison of acute kidney injury during treatment with vancomycin in combination with piperacillin-tazobactam or cefepime. / Gomes, Diane M.; Smotherman, Carmen; Birch, Amy; Dupree, Lori; Della Vecchia, Bethany J.; Kraemer, Dale; Jankowski, Christopher A.

In: Pharmacotherapy, Vol. 34, No. 7, 01.01.2014, p. 662-669.

Research output: Contribution to journalArticle

Gomes, DM, Smotherman, C, Birch, A, Dupree, L, Della Vecchia, BJ, Kraemer, D & Jankowski, CA 2014, 'Comparison of acute kidney injury during treatment with vancomycin in combination with piperacillin-tazobactam or cefepime', Pharmacotherapy, vol. 34, no. 7, pp. 662-669. https://doi.org/10.1002/phar.1428
Gomes, Diane M. ; Smotherman, Carmen ; Birch, Amy ; Dupree, Lori ; Della Vecchia, Bethany J. ; Kraemer, Dale ; Jankowski, Christopher A. / Comparison of acute kidney injury during treatment with vancomycin in combination with piperacillin-tazobactam or cefepime. In: Pharmacotherapy. 2014 ; Vol. 34, No. 7. pp. 662-669.
@article{8910ce01e97a427b914c05ba2fec349e,
title = "Comparison of acute kidney injury during treatment with vancomycin in combination with piperacillin-tazobactam or cefepime",
abstract = "Study Objective To evaluate the observed incidence of acute kidney injury (AKI) in adult patients receiving either piperacillin-tazobactam and vancomycin or cefepime-vancomycin for more than 48 hours. Design Retrospective matched cohort. Setting Large academic medical center. Patients Adult patients without preexisting renal dysfunction admitted over an 8-month time period who received either the combination of piperacillin-tazobactam and vancomycin or cefepime-vancomycin for more than 48 hours were evaluated for AKI, defined by the Acute Kidney Injury Network criteria. Measurements and Main Results A total of 224 patients receiving either antimicrobial combination were evaluated for AKI. The incidence of AKI was significantly higher in the piperacillin- tazobactam and vancomycin group (34.8{\%}) compared with the cefepime-vancomycin group (12.5{\%}) in the unmatched analysis (p<0.0001). After adjusting for potential sources of bias through propensity score matched pairs and conditional logistic regression, piperacillin-tazobactam and vancomycin combination therapy (p=0.003) was an independent predictor of AKI. There were no significant differences in time to AKI or hospital length of stay between groups. Conclusions The results of this study suggest that there may be an association between piperacillin-tazobactam and vancomycin combination therapy and increased incidence of AKI.",
keywords = "acute kidney injury, cefepime, nephrotoxicity, piperacillin-tazobactam, vancomycin",
author = "Gomes, {Diane M.} and Carmen Smotherman and Amy Birch and Lori Dupree and {Della Vecchia}, {Bethany J.} and Dale Kraemer and Jankowski, {Christopher A.}",
year = "2014",
month = "1",
day = "1",
doi = "10.1002/phar.1428",
language = "English (US)",
volume = "34",
pages = "662--669",
journal = "Pharmacotherapy",
issn = "0277-0008",
publisher = "Pharmacotherapy Publications Inc.",
number = "7",

}

TY - JOUR

T1 - Comparison of acute kidney injury during treatment with vancomycin in combination with piperacillin-tazobactam or cefepime

AU - Gomes, Diane M.

AU - Smotherman, Carmen

AU - Birch, Amy

AU - Dupree, Lori

AU - Della Vecchia, Bethany J.

AU - Kraemer, Dale

AU - Jankowski, Christopher A.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Study Objective To evaluate the observed incidence of acute kidney injury (AKI) in adult patients receiving either piperacillin-tazobactam and vancomycin or cefepime-vancomycin for more than 48 hours. Design Retrospective matched cohort. Setting Large academic medical center. Patients Adult patients without preexisting renal dysfunction admitted over an 8-month time period who received either the combination of piperacillin-tazobactam and vancomycin or cefepime-vancomycin for more than 48 hours were evaluated for AKI, defined by the Acute Kidney Injury Network criteria. Measurements and Main Results A total of 224 patients receiving either antimicrobial combination were evaluated for AKI. The incidence of AKI was significantly higher in the piperacillin- tazobactam and vancomycin group (34.8%) compared with the cefepime-vancomycin group (12.5%) in the unmatched analysis (p<0.0001). After adjusting for potential sources of bias through propensity score matched pairs and conditional logistic regression, piperacillin-tazobactam and vancomycin combination therapy (p=0.003) was an independent predictor of AKI. There were no significant differences in time to AKI or hospital length of stay between groups. Conclusions The results of this study suggest that there may be an association between piperacillin-tazobactam and vancomycin combination therapy and increased incidence of AKI.

AB - Study Objective To evaluate the observed incidence of acute kidney injury (AKI) in adult patients receiving either piperacillin-tazobactam and vancomycin or cefepime-vancomycin for more than 48 hours. Design Retrospective matched cohort. Setting Large academic medical center. Patients Adult patients without preexisting renal dysfunction admitted over an 8-month time period who received either the combination of piperacillin-tazobactam and vancomycin or cefepime-vancomycin for more than 48 hours were evaluated for AKI, defined by the Acute Kidney Injury Network criteria. Measurements and Main Results A total of 224 patients receiving either antimicrobial combination were evaluated for AKI. The incidence of AKI was significantly higher in the piperacillin- tazobactam and vancomycin group (34.8%) compared with the cefepime-vancomycin group (12.5%) in the unmatched analysis (p<0.0001). After adjusting for potential sources of bias through propensity score matched pairs and conditional logistic regression, piperacillin-tazobactam and vancomycin combination therapy (p=0.003) was an independent predictor of AKI. There were no significant differences in time to AKI or hospital length of stay between groups. Conclusions The results of this study suggest that there may be an association between piperacillin-tazobactam and vancomycin combination therapy and increased incidence of AKI.

KW - acute kidney injury

KW - cefepime

KW - nephrotoxicity

KW - piperacillin-tazobactam

KW - vancomycin

UR - http://www.scopus.com/inward/record.url?scp=84903883207&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84903883207&partnerID=8YFLogxK

U2 - 10.1002/phar.1428

DO - 10.1002/phar.1428

M3 - Article

VL - 34

SP - 662

EP - 669

JO - Pharmacotherapy

JF - Pharmacotherapy

SN - 0277-0008

IS - 7

ER -